Loading...

XOMA

DB:X0M1
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
X0M1
DB
$108M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
X0M1 Share Price and Events
7 Day Returns
-5.4%
DB:X0M1
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-45%
DB:X0M1
-7.4%
DE Biotechs
-5.6%
DE Market
X0M1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
XOMA (X0M1) -5.4% -5% -1.5% -45% -30% -83.1%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • X0M1 underperformed the Biotechs industry which returned -7.4% over the past year.
  • X0M1 underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
X0M1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is XOMA undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for XOMA. This is due to cash flow or dividend data being unavailable. The share price is €11.006.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for XOMA's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are XOMA's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:X0M1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.59
NasdaqGM:XOMA Share Price ** NasdaqGM (2019-04-24) in USD $12.4
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of XOMA.

DB:X0M1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:XOMA Share Price ÷ EPS (both in USD)

= 12.4 ÷ -1.59

-7.78x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • XOMA is loss making, we can't compare its value to the Europe Biotechs industry average.
  • XOMA is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does XOMA's expected growth come at a high price?
Raw Data
DB:X0M1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.78x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
41.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for XOMA, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on XOMA's assets?
Raw Data
DB:X0M1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.16
NasdaqGM:XOMA Share Price * NasdaqGM (2019-04-24) in USD $12.4
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:X0M1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:XOMA Share Price ÷ Book Value per Share (both in USD)

= 12.4 ÷ 2.16

5.74x

* Primary Listing of XOMA.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • XOMA is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess XOMA's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. XOMA has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is XOMA expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
41.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is XOMA expected to grow at an attractive rate?
  • XOMA's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • XOMA's earnings growth is expected to exceed the Germany market average.
  • XOMA's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:X0M1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:X0M1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 41.3%
DB:X0M1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 31.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:X0M1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:X0M1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 27 6 3
2022-12-31 19 -1 3
2021-12-31 11 -9 3
2020-12-31 7 -14 3
2019-12-31 9 -12 3
DB:X0M1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 5 -13 -13
2018-09-30 9 -15 -11
2018-06-30 44 18 16
2018-03-31 53 13 18
2017-12-31 53 3 6
2017-09-30 48 15 -11
2017-06-30 12 -28 -39
2017-03-31 2 -32 -61
2016-12-31 6 -34 -54
2016-09-30 53 -12 -11
2016-06-30 55 -19 1
2016-03-31 57 -23 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • XOMA's earnings are expected to grow significantly at over 20% yearly.
  • XOMA's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:X0M1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from XOMA Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:X0M1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.24 1.51 -0.45 3.00
2022-12-31 -0.46 1.19 -1.83 3.00
2021-12-31 -1.07 0.01 -2.06 3.00
2020-12-31 -1.47 -0.94 -2.33 3.00
2019-12-31 -1.41 -0.75 -1.75 3.00
DB:X0M1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.59
2018-09-30 -1.35
2018-06-30 1.96
2018-03-31 2.29
2017-12-31 0.75
2017-09-30 -1.54
2017-06-30 -5.94
2017-03-31 -9.84
2016-12-31 -8.89
2016-09-30 -1.78
2016-06-30 0.23
2016-03-31 -1.22

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if XOMA will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess XOMA's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
XOMA has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has XOMA performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare XOMA's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • XOMA does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare XOMA's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare XOMA's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
XOMA's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from XOMA Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:X0M1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 5.30 -13.34 18.56
2018-09-30 8.97 -11.23 20.95
2018-06-30 44.26 15.99 23.55
2018-03-31 52.89 18.23 24.34
2017-12-31 52.69 5.71 24.34
2017-09-30 47.86 -10.87 22.81 42.83
2017-06-30 12.31 -39.43 19.61 42.83
2017-03-31 1.86 -61.48 19.18 42.83
2016-12-31 5.56 -53.53 18.32 42.83
2016-09-30 53.22 -10.70 18.55 11.44
2016-06-30 54.66 1.35 20.12 23.44
2016-03-31 56.76 -7.25 20.41 37.34
2015-12-31 55.45 -20.61 20.62 50.15
2015-09-30 11.61 -53.28 20.01 52.19
2015-06-30 14.67 -67.19 19.73 52.78
2015-03-31 18.11 -55.33 19.83 49.98
2014-12-31 18.87 -38.30 19.87 51.28
2014-09-30 27.05 -83.28 20.82 86.14
2014-06-30 28.23 -98.51 20.69 53.62
2014-03-31 29.41 -103.86 19.61 62.46
2013-12-31 35.45 -124.06 18.48 47.49
2013-09-30 30.31 -69.39 17.38 6.67
2013-06-30 31.25 -66.62 16.82 35.07
2013-03-31 33.37 -65.53 16.31 23.85
2012-12-31 33.78 -71.07 16.87 30.53
2012-09-30 36.24 -85.17 17.45 28.02
2012-06-30 45.22 -64.86 18.78 25.16

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if XOMA has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if XOMA has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if XOMA improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess XOMA's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
XOMA has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is XOMA's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up XOMA's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • XOMA is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • XOMA's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of XOMA's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from XOMA Company Filings, last reported 3 months ago.

DB:X0M1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 18.79 22.48 45.78
2018-09-30 1.15 22.03 28.43
2018-06-30 4.85 14.85 38.69
2018-03-31 5.64 14.57 41.97
2017-12-31 5.79 14.57 43.47
2017-09-30 4.06 14.32 47.75
2017-06-30 -29.12 27.86 12.47
2017-03-31 -31.21 26.63 20.05
2016-12-31 -47.21 43.17 25.74
2016-09-30 -31.19 45.22 20.62
2016-06-30 -20.45 46.52 34.30
2016-03-31 -7.53 46.25 46.61
2015-12-31 -2.31 48.67 66.26
2015-09-30 -29.19 48.59 32.05
2015-06-30 -31.29 48.00 50.96
2015-03-31 -13.38 47.19 67.49
2014-12-31 3.10 35.31 78.45
2014-09-30 -18.13 36.59 59.06
2014-06-30 -7.57 38.30 75.89
2014-03-31 1.74 38.74 93.70
2013-12-31 -3.99 40.99 121.65
2013-09-30 -13.54 41.03 73.99
2013-06-30 -16.86 40.96 57.93
2013-03-31 -0.91 41.10 70.38
2012-12-31 21.47 41.04 85.33
2012-09-30 -20.28 40.00 59.20
2012-06-30 3.86 35.47 66.91
  • XOMA's level of debt (119.7%) compared to net worth is high (greater than 40%).
  • XOMA had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • XOMA has sufficient cash runway for 1.7 years based on current free cash flow.
  • XOMA has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of -33.1% each year.
X
Financial health checks
We assess XOMA's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. XOMA has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is XOMA's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from XOMA dividends.
If you bought €2,000 of XOMA shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate XOMA's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate XOMA's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:X0M1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:X0M1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as XOMA has not reported any payouts.
  • Unable to verify if XOMA's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of XOMA's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as XOMA has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess XOMA's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can XOMA afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. XOMA has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of XOMA's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jim Neal
COMPENSATION $4,164,385
AGE 62
TENURE AS CEO 2.3 years
CEO Bio

Mr. James R. Neal, also known as Jim, has been the Chief Executive Officer at XOMA Corporation since December 21, 2016 and served as its Chief Operating Officer and Senior Vice President from November 1, 2015 to December 21, 2016 and served as its Vice President of Business Development from November 2009 to November 1, 2015. Mr. Neal has more than 25 years' experience forming and maximizing valuable business and technology collaborations globally and in taking novel products and technologies to market. Mr. Neal served as Chief Executive Officer and President of Entelos, Inc. He served as Chief Business Officer of Entelos, Inc. He served as Chief Executive Officer of Iconix BioSciences, Inc. since June 2002. He joined Iconix Pharmaceuticals, Inc., in June 2002. He served as Executive Vice President of Sales, Marketing and Business Development and a Member of the Executive Team at Incyte Corporation (Incyte Genomics) from 1999 to 2002. He was responsible for Incyte's global commercial activities with clients and collaborators. He joined Incyte as an Executive Officer in July 1999. Prior to Incyte, he served as General Manager of the Solaris Group, a division of Monsanto Company. Mr. Neal served various positions of increasing responsibility with Monsanto from 1982 to 1999. He has been a Director of XOMA Corporation since December 21, 2016. He served as a Director of Iconix BioSciences, Inc. Mr. Neal has his B. Sc. degree in Biology and his M. Sc. in Genetics and Plant Breeding from the University of Manitoba, Canada. He completed an Executive MBA at Washington University in 1992.

CEO Compensation
  • Jim's compensation has increased whilst company is loss making.
  • Jim's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the XOMA management team in years:

1.8
Average Tenure
43.5
Average Age
  • The average tenure for the XOMA management team is less than 2 years, this suggests a new team.
Management Team

Jim Neal

TITLE
CEO & Director
COMPENSATION
$4M
AGE
62
TENURE
2.3 yrs

Tom Burns

TITLE
Senior VP of Finance & CFO
COMPENSATION
$2M
AGE
44
TENURE
4 yrs

Danny Hart

TITLE
VP & General Counsel
AGE
42
TENURE
1.3 yrs

Dee Datta

TITLE
Chief Business Officer
AGE
43
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the XOMA board of directors in years:

4.3
Average Tenure
62
Average Age
  • The tenure for the XOMA board of directors is about average.
Board of Directors

Denny Van Ness

TITLE
Chairman of the Board & Lead Independent Director
COMPENSATION
$180K
AGE
75
TENURE
7.7 yrs

Jim Neal

TITLE
CEO & Director
COMPENSATION
$4M
AGE
62
TENURE
2.3 yrs

Jack Wyszomierski

TITLE
Independent Director
COMPENSATION
$143K
AGE
62
TENURE
8.7 yrs

Joe Limber

TITLE
Independent Director
COMPENSATION
$134K
AGE
65
TENURE
6.3 yrs

Barbara Kosacz

TITLE
Director
AGE
59
TENURE
0.3 yrs

Matthew Perry

TITLE
Independent Director
COMPENSATION
$147K
AGE
45
TENURE
2.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Dec 18 Buy BVF Partners LP Company 17. Dec 18 17. Dec 18 25,000 €12.51 €312,750
13. Dec 18 Buy BVF Partners LP Company 11. Dec 18 13. Dec 18 36,463 €12.99 €464,342
11. Dec 18 Buy BVF Partners LP Company 06. Dec 18 10. Dec 18 61,023 €13.02 €789,485
05. Dec 18 Buy BVF Partners LP Company 30. Nov 18 04. Dec 18 9,800 €13.20 €128,705
29. Nov 18 Buy BVF Partners LP Company 27. Nov 18 29. Nov 18 29,700 €13.39 €394,128
21. Nov 18 Buy BVF Partners LP Company 19. Nov 18 21. Nov 18 72,253 €13.16 €898,055
19. Nov 18 Buy BVF Partners LP Company 15. Nov 18 16. Nov 18 31,990 €12.12 €378,249
15. Nov 18 Buy James Neal Individual 13. Nov 18 13. Nov 18 4,000 €11.75 €47,013
X
Management checks
We assess XOMA's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. XOMA has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Details
Name: XOMA Corporation
X0M1
Exchange: DB
Founded: 1981
$96,537,127
8,713,209
Website: http://www.xoma.com
Address: XOMA Corporation
2200 Powell Street,
Suite 310,
Emeryville,
California, 94608,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM XOMA Common Stock Nasdaq Global Market US USD 06. Jun 1986
DB X0M1 Common Stock Deutsche Boerse AG DE EUR 06. Jun 1986
LSE 0M26 Common Stock London Stock Exchange GB USD 06. Jun 1986
Number of employees
Current staff
Staff numbers
11
XOMA employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 20:41
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/16
Last earnings filing: 2019/03/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.